$2.59 Billion is the total value of Artal Group S.A.'s 99 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVRO | Exit | AVROBIO INC | $0 | – | -23,449 | -100.0% | -0.01% | – |
| SQ | Exit | SQUARE INCcl a | $0 | – | -30,000 | -100.0% | -0.08% | – |
| GRTS | Exit | GRITSTONE ONCOLOGY INC | $0 | – | -250,000 | -100.0% | -0.09% | – |
| ALLO | Exit | ALLOGENE THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.11% | – |
| NIO | Exit | NIO INCsponsored ads | $0 | – | -2,000,000 | -100.0% | -0.12% | – |
| TORC | Exit | RESTORBIO INC | $0 | – | -500,000 | -100.0% | -0.18% | – |
| ARQL | Exit | ARQULE INC | $0 | – | -850,000 | -100.0% | -0.24% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -500,000 | -100.0% | -0.36% | – |
| BOLD | Exit | AUDENTES THERAPEUTICS INC | $0 | – | -350,000 | -100.0% | -0.39% | – |
| FIS | Exit | FIDELITY NATL INFORMATION SV | $0 | – | -75,000 | -100.0% | -0.40% | – |
| DLPH | Exit | DELPHI TECHNOLOGIES PLCcall | $0 | – | -750,000 | -100.0% | -0.40% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.62% | – |
| BABA | Exit | ALIBABA GROUP HLDG LTDcall | $0 | – | -100,000 | -100.0% | -0.67% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -350,000 | -100.0% | -0.68% | – |
| XBI | Exit | SPDR SERIES TRUSTcall | $0 | – | -250,000 | -100.0% | -0.76% | – |
| NVDA | Exit | NVIDIA CORP | $0 | – | -200,000 | -100.0% | -1.40% | – |
| MDCO | Exit | MEDICINES CO | $0 | – | -1,400,000 | -100.0% | -2.81% | – |
| BAC | Exit | BANK AMER CORPcall | $0 | – | -3,000,000 | -100.0% | -3.51% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB COcall | $0 | – | -3,500,000 | -100.0% | -7.12% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-06-22 |
| 3 | 2023-06-15 |
| 4 | 2023-06-05 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.